The FDA has asked Sarepta to reveal results of muscle biopsies to see how much new dystrophin was made after treatment with eteplirsen, but haven’t they already said studies only showed 0.9% increase? Will this new release provide any new information and give hope to Sarepta investors, not to mention patients and families, or is it just a rehash of old data which will only give the FDA cover for disapproving the drug? RNP,MD
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.